<DOC>
	<DOC>NCT00747149</DOC>
	<brief_summary>This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step after 6 weeks of therapy in type 2 diabetic patients previously treated with another statin and not at LDL-C targets.</brief_summary>
	<brief_title>A Diabetes Study to Treat A Population Previously Not at Target</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Diagnosis of Type 2 diabetes Previously treated with a commonly accepted start dose of a statin for the last 4 weeks prior to study entry Fasting LDLC concentration of &gt; 2.0 mmol/L (and ≤ 5.0 mmol/L) (in the past 3 months) History of serum TG level of ≤ 4.6 mmol/l (in the past 3 months) If currently receiving therapy with any statin at a dose higher than listed Rosuvastatin (current use) Fibrates, niacin or resins that was not discontinued a minimum of 2 months prior to enrolment. Type 1 diabetes; glycated haemoglobin (HbA1c) &gt; 9.0% Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 1.5 × upper limit of normal (ULN) (in the past 2 months) Resting diastolic or systolic blood pressure of &gt; 95 mmHg or &gt; 180 mmHg, respectively (in the past 2 months) Unexplained serum creatine kinase (CK) level &gt; 3 × ULN (in the past 2 months).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2</keyword>
</DOC>